LOGIN
ID
PW
MemberShip
2023-06-02 18:14
All News
Policy
Company
Product
Opinion
InterView
검색
Dailypharm Live Search
Close
Roche 2018 Annualreport
Roche 2018 Annualreport
2019-12-23
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2019-12-23
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
2019-11-15
Risk-Sharing Agreements in the EU: A Systematic Review
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends
2019-11-15
Managed Entry Agreements for
Managed Entry Agreements for Oncology Drugs
2019-11-15
OPINION
[Reporter’s View] Please wait for policies to take effect
Reporter's view |
Lee, Tak-Sun
Are you ready to use
Reporter's view |
Lee, Hye-Kyung
[Reporter’s View] Bitter ERPs following spin-offs and sales
Reporter's view |
Eo, Yun-Ho
INTERVIEW
The use of HTN combi tx in Korea is the highest in the world
‘Even a 0.2 vision is a miracle to some’
Samsung Bio, investing in Swiss ADC bio company
CDK4/6 latecomer Kisqali exudes confidence in its effect
Seock-Ah Im, Professor of Hemato-Oncology at Seoul National University Hospital
The rebate effect is not just employee deviation
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
2 K-biosimilars are approved in the US and Europe per year
2
Keytruda is expected to enter the domestic market
3
Sales of Keytruda rose 117%
4
K-Pharma Bio ASCO launch table
5
Vemlidy IMDs compete with lower price
6
Samsung Bioepis, Soliris biosimilar approved in Europe
7
Verzenio prescribing guideline recommendations
8
↓Sales of Nexavar and Lenvima &↑Sales of Cabometyx
9
The share of the domestic bio-industry is around 1%
10
Lyumjev can be prescribed at general hospitals
